Chimeric antigen receptor (CAR) T cells have been successfully used against treatment-resistant blood cancers. Now, scientists have demonstrated that they can potentially be engineered to treat senescence-related diseases, such as atherosclerosis, diabetes, osteoarthritis and liver fibrosis. Scientists at Memorial Sloan Kettering Cancer Center (NY, USA) have demonstrated that CAR-T cells have applications beyond treating blood cancers by successfully engineering them to treat liver fibrosis – a disease linked to senescence – in murine models. Senescence is a permanent state of cell-cycle arrest where cells secrete a range of pro-inflammatory factors. Senescence is thought to be caused by cellular stress, DNA...
To view this content, please register now for access
Join our member community for FREE to access a collection of journal and online-only features, including:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news and journal updates delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!